Figure 2.
Kaplan-Meier curves for PFS according to the PD-L1 expression level and EGFR mutation status in patients treated with (A) osimertinib or (B) first- and second-generation EGFR-TKIs. EGFR-TKIs, epidermal growth factor receptor-tyrosine kinase inhibitors; PD-L1, programmed death ligand-1; PFS, progression-free survival.
